Scientific Program

Thursday, May 10, 2007

Noon - 7:00 PM Registration
6:00 - 8:00 PM Welcome Wine and Cheese Reception for all Attendees and Exhibitors- Poolside

Friday, May 11, 2007

7:00-8:00 AM

BREAKFAST in the Exhibits (On site registration available)
Session I.   Risk Factors Affecting Survival in Recipients of Cord Blood
8:00 - 8:30 Review Lecture: Analysis of risk factors affecting survival after UCBT in children and adults with hematological malignancy. Vanderson Rocha, Hôpital St. Louis, Paris, France.
8:30 - 8:45 Analysis of risk factors in adults transplanted with UCB for treatment of hematologic malignancy. Guillermo Sanz, Hospital Universitario La Fe, Valencia, Spain.
8:45 - 9:00 Impact of Host-versus-Graft HLA mismatches on survival after UCBT. Marcos de Lima, MD Anderson Cancer Center, Houston, TX.
9:00 - 9:15 HLA-matched and mismatched UCB versus HLA- A, B, C, DRB1 allele-matched bone marrow: comparison of outcomes and analysis of risk factors. Mary Eapen, CIBMTR, Milwaukee, WI.
9:15 - 9:30 Risk factor analysis in UCBT in patients with non-malignant disease. Eliane Gluckman, Eurocord, Paris, France.
9:30 - 10:00 COFFEE BREAK in the Exhibits
Session II.   Strategies to Improve Engraftment after UCBT
10:00 - 10:30 Review Lecture: Factors afffecting engraftment after UCBT. John Wagner, University of Minnesota, Minneapolis, MN.
10:30 - 10:45 Influence of HLA disparity and graft lymphocytes on allogeneic engraftment and survival after UCB transplant in adults. Mary J. Laughlin, Case Western Reserve University, Cleveland, OH.
10:45 - 11:00 Impact of double unit and fludarabine on engraftment after myeloablative conditioning and UCBT. John Wagner, University of Minnesota, MN.
11:00 - 11:15 Effect of CD26 inhibition on cord blood and other means to enhance engraftment. Hal Broxmeyer, Indiana University School of Medicine, Indianapolis, IN.
11:15 - 11:30 Hypomethylating agents for ex-vivo expansion of UCB progenitor cells. Ron Hoffman, University of Illinois, Chicago, IL.
11:30 - 11:45 Glycogen synthase kinase-3β regulates ex-vivo expansion and engraftment of umbilical cord blood hematopoietic stem cells through the activation of Wnt signaling. Tracey A. O' Brien, Sydney Children's Hospital, Sydney, NSW, Australia.
11:45 - Noon Delta1: A Notch Up on Cord Blood Transplantation? Colleen Delaney, Fred Hutchinson Cancer Center, Seattle, WA
Noon - 1:15 PM LUNCH in the Exhibits & Century Pavilion
Session II. (continued)
1:15 - 1:30 Mesenchymal stem cells for expansion of cord blood stem cells. Elizabeth J. Shpall, MD Anderson Cancer Center, Houston, TX.
1:30 - 1:45 PTH to enhance homing and engraftment after UCBT. David Scadden, Harvard University, Boston, MA.
1:45 - 2:00 Ex-vivo expansion of ALDH bright cells. Joanne Kurtzberg, Duke University, Durham, NC
2:00 - 2:15 Primary graft failure after unrelated donor UCBT: risk factors and management. Ka Wah Chan, Texas Transplant Institute, San Antonio, TX.
2:15 - 2:30 Direct intra-bone transplant of unrelated cord blood cells is associated with fast and complete hematologic recovery: time to change the intravenous route? Francesco Frassoni, Ospedale San Martino, Genova, Italy.
2:30 - 2:45 Panel discussion with audience participation
2:45 - 3:15 COFFEE BREAK in the Exhibits
Session III.   Cord Blood Banking, Manipulation and Unit Selection
3:15 - 3:45 Discussion: When should cord blood units be used for transplantation? A discussion by two transplant physicians - one who uses cord frequently and one who does not. Dr. John Wagner and Dr. Robertson Parkman. Moderator: Dr. Richard Champlin
3:45 - 4:00 UCB unit selection. Cladd Stevens, New York Blood Center, New York, NY.
4:00 - 4:15 UCB unit selection. Eliane Gluckman, Hôptial St. Louis, Paris, France
4:15 - 4:30 A "no-wash" albumin-dextran dilution strategy for UCB thaw for adolescent and adult UCB transplant recipients: superior to wash? Juliet Barker, Memorial Sloan-Kettering Cancer Center, New York, NY.
4:30 - 5:00 Panel discussion with audience participation
5:00 PM ADJOURN

Saturday, May 12, 2007

7:00-8:00 AM

BREAKFAST in the Exhibits
(Registration desk will be open for single-day registrations)
Session IV.   Conditioning Regimens
8:00 - 8:30 Review Lecture: Reduced intensity conditioning regimens for reduction of toxicity of HSCT. Richard Champlin, MD Anderson Cancer Center, Houston, TX
8:30 - 8:45 UCBT after reduced intensity conditioning. Claudio G. Brunstein, University of Minnesota, Minneapolis, MN.
8:45 - 9:00 Reduced intensity conditioning regimen in single unrelated UCBT in adults with hematological malignant disorders. An Eurocord-Netcord and SFGM-TC survey. Vanderson Rocha, Hôpital St. Louis, Paris, France
9:00 - 9:15 Outcomes of 40 adult patients after double UCBT using a reduced intensity chemotherapy conditioning regimen. Karen K. Ballen, Massachusetts General Hospital, Boston, MA.
Session V.   Immune Reconstitution and Infections
9:15 - 9:45 Review Lecture: Infection and immune reconstitution after HSCT: Challenges and Opportunities. Bruce Blazar, University of MInnesota, MN.
9:45 - 10:15 COFFEE BREAK in the Exhibits
10:15 - 10:45 Multivariate analysis of patient and graft specific factors in recipients of unrelated UCBT to predict risk of death from opportunistic infections in the first 6 months. Paul Szabolcs, Duke University, Durham, NC.
10:45 - 11:00 Delayed immune recovery after UCBT is characterized by thymic regeneration failure. Krishna Komanduri, MD Anderson Cancer Institute, Houston, TX.
11:00 - 11:15 UCB-derived dendritic/T cells generating adenoviral-specific killing. Catherine Bollard, Baylor College of Medicine, Houston, TX.
11:15 - 11:30 Rapid monitoring of multiple pathogens and infusion of ex vivo-expanded donor CD4-T cell (CD4-DLI). Tomohiro Morio, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
11:30 - 11:45 Panel discussion with audience participation
11:45 AM - 1:00 PM LUNCH in the Exhibits & Century Pavilion
Session VI.   Non-Hematopoietic Stem Cells
1:00 - 1:30 Review Lecture: Non-Hematopoietic Stem Cells. Mark L. Weiss, Kansas State University, Manhattan, KS
1:30 - 1:45 Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic (VSEL) stem cells purified from human cord blood. Mariusz A. Ratajczak, University of Louisville, Louisville, KY
1:45 - 2:00 High proliferative endothelial progenitor cells found in UCB. Mervin C. Yoder, Jr. Indiana University, Indianapolis, IN.
2:00 - 2:15 Differentiation of UCB-derived multilineage progenitor cells into respiratory epithelial cells. David McKenna, University of Minnesota, Minneapolis, MN
2:15 - 2:30 Progress in regenerative medicine using cord blood: Mesenchymal stem cell isolation and induction to bone and cartilage. Tsuneo A. Takahashi, The University of Tokyo, Japan.
2:30 - 3:00 COFFEE BREAK in the Exhibits
Session VII.   The Graft versus Tumor Effect
3:00 - 3:15 Double umbilical cord blood transplantation to reduce the risk of relapse in UCBT. Michael Verneris, University of Minnesota, Minneapolis, MN
3:15 - 3:30 UCB NK cell immunotherapy and double UCBT in patients with refractory AML. Jeffrey S. Miller, University of Minnesota, Minneapolis, MN
3:30 - 3:45 Ex-vivo expansion and mRNA transfection of cord blood derived natural killer cells. Hans G. Klingemann, Tufts-New England Medical Center, Boston, MA
Session VIII.   Governmental Affairs
3:45 - 4:05 Implementing the Stem Cell Therapeutic and Research Act of 2005: a report from the Health Resources Services Administration. Robert Baitty, HRSA, Rockville, MD
4:05 - 4:25 The development of the National Cord Blood Center. Dennis Confer, NMDP, Minneapolis, MN
4:25 - 4:45 The Food and Drug Administration and UCB banking and transplantation. Ellen Lazarus, US FDA, Rockville, MD
4:45 - 5:00 Panel discussion with audience participation
5:00 PM ADJOURN